Target intelligence / Profile preview

Influenza Hemagglutinin Antigen H3N2 Subtype A Virus Protein (HA)

Target
HA
Molecular classification
Glycoprotein, Viral protein, Surface antigen
01

Overview

The hemagglutinin (HA) antigen of the influenza A virus subtype H3N2 is a surface glycoprotein crucial for viral entry. It mediates binding to host cell receptors containing sialic acid, initiating infection through membrane fusion. HA is a trimeric protein, with each monomer composed of HA1 and HA2 subunits. Antigenic drift, especially in the receptor-binding site, and glycan shielding contribute to immune evasion, necessitating frequent updates to vaccine strains. HA is a primary target for neutralizing antibodies and antiviral interventions. Mutations at positions 226 and 228 in HA are key determinants of host range and receptor specificity.

Other names
HemagglutininH3N2 HemagglutininHA H3N2
02

Mechanism of action

Facilitates viral entry into host cells by binding to sialic acid receptors and mediating membrane fusion. Neutralizing antibodies against HA prevent binding or fusion.

03

Biological functions

Viral entryReceptor bindingMembrane fusionImmune evasion
04

Disease associations

InfluenzaSeasonal epidemicsViral infection
05

Safety considerations

Antigenic drift leading to vaccine mismatchPotential for mutations altering receptor specificity (e.g., increasing affinity for human receptors)Glycan shielding hindering antibody recognition
06

Interacting drugs

NA inhibitors (e.g., Oseltamivir, Zanamivir): Indirectly, by preventing viral release)

1 more in the full profile.

07

Biomarkers

HA sequence variations (for vaccine strain selection)Antibody titers against HA (for assessing vaccine efficacy)N-glycosylation site patterns (for tracking antigenic drift)

Beyond the preview

Go deeper on Influenza Hemagglutinin Antigen H3N2 Subtype A Virus Protein (HA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Influenza Hemagglutinin Antigen H3N2 Subtype A Virus Protein (HA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call